Rituximab Therapy of B-Cell Neoplasms

This publication has 30 references indexed in Scilit:

• Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
  Journal of Clinical Oncology, 2000
• Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma
  Clinical Lymphoma, 2000
• Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
  Annals of Oncology, 2000
• Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
  Annals of Oncology, 2000
• Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
  Annals of Oncology, 2000
• Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody
  Japanese Journal of Cancer Research, 1998
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
  New England Journal of Medicine, 1994
• Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation
  New England Journal of Medicine, 1991
• Continuous cultures of fused cells secreting antibody of predefined specificity
  Nature, 1975